Mitchell Chan
Director/Board Member chez AVALO THERAPEUTICS, INC.
Profil
Mitchell Chan is an Independent Director at Avalo Therapeutics, Inc. and a Director at Maryland Technology Council.
He was previously a Director-Investor Relations at AstraZeneca PLC and the Chief Financial & Accounting Officer at Viela Bio, Inc. He holds an MBA from Rotman School of Management and undergraduate and graduate degrees from the University of Toronto.
Postes actifs de Mitchell Chan
| Sociétés | Poste | Début |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Director/Board Member | 01/12/2021 |
Maryland Technology Council
 Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Director/Board Member | 11/03/2020 |
Anciens postes connus de Mitchell Chan
| Sociétés | Poste | Fin |
|---|---|---|
| VIELA BIO, INC. | Director of Finance/CFO | 15/03/2021 |
| ASTRAZENECA PLC | Investor Relations Contact | - |
Formation de Mitchell Chan
| Rotman School of Management | Masters Business Admin |
| University of Toronto | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| AVALO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Maryland Technology Council
Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Commercial Services |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
